The US 🇺🇸 American FDA has Eli Lilly's
$LLY (+1,78%) weight loss drug Zepbound for the treatment of patients with sleep apnea, CNBC reports.
Graphic: REUTERS/Mike Segar
The US 🇺🇸 American FDA has Eli Lilly's
$LLY (+1,78%) weight loss drug Zepbound for the treatment of patients with sleep apnea, CNBC reports.
Graphic: REUTERS/Mike Segar